Deutsche Bank Ag\ An2 Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$13.92 - $21.0 $549,450 - $828,912	39,472 New	39,472 $808,000
Q1 2023 May 15, 2023	BUY	$7.94 - $15.6 $16,086 - $31,605	2,026 Added 42.31%	6,815 $67,000
Q4 2022 Feb 13, 2023	BUY	$8.51 - $19.69 $24,704 - $57,160	2,903 Added 153.92%	4,789 $45,000
Q3 2022 Nov 14, 2022	SELL	$7.61 - $22.29 $2,359 - $6,909	-310 Reduced 14.12%	1,886 $33,000
Q2 2022 Aug 11, 2022	BUY	$7.7 - $18.82 $16,909 - $41,328	2,196 New	2,196 $17,000

13.7M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $22.1M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.